Pervasis Therapeutics, Cambridge, MA, USA.
J Vasc Surg. 2012 Oct;56(4):1078-88. doi: 10.1016/j.jvs.2012.03.002. Epub 2012 Jul 15.
High restenosis rates are a limitation of peripheral vascular interventions. Previous studies have shown that surgical implantation of a tissue-engineered endothelium onto the adventitia surface of injured vessels regulates vascular repair. In the present study, we developed a particulate formulation of tissue-engineered endothelium and a method to deliver the formulation perivascular to injured blood vessels using a percutaneous, minimally invasive technique.
Stainless steel stents were implanted in 18 balloon-injured femoral arteries of nine domestic swine, followed by ultrasound-guided percutaneous perivascular injection of gelatin particles containing cultured allogeneic porcine aortic endothelial cells (PAE). Controls received injections of empty particles (matrix) or no perivascular injection (sham) after stent deployment. Animals were sacrificed after 90 days.
Angiographic analysis revealed a significantly greater lumen diameter in the stented segments of arteries treated with PAE/matrix (4.72 ± 0.12 mm) compared with matrix (4.01 ± 0.20 mm) or sham (4.03 ± 0.16 mm) controls (P < .05). Similarly, histologic analysis revealed that PAE/matrix-treated arteries had the greatest lumen area (20.4 ± 0.7 mm(2); P < .05) compared with controls (16.1 ± 0.9 mm(2) and 17.1 ± 1.0 mm(2) for sham and matrix controls, respectively) and the smallest intimal area (3.3 ± 0.4 mm(2); P < .05) compared with controls (6.2 ± 0.5 mm(2) and 4.4 ± 0.5 mm(2) for sham and matrix controls, respectively). Overall, PAE-treated arteries had a 33% to 50% decrease in percent occlusion (P < .05) compared with controls. Histopathological analysis revealed fewer leukocytes present in the intima in the PAE/matrix group compared with control groups, suggesting that the biological effects were in part due to inhibition of the inflammatory phase of the vascular response to injury.
Minimally invasive, perivascular delivery of PAE/matrix to stented arteries was performed safely using ultrasound-guided percutaneous injections and significantly decreased stenosis. Application at the time of or subsequent to peripheral interventions may decrease clinical restenosis rates.
外周血管介入治疗的一个局限性是再狭窄率较高。先前的研究表明,将组织工程化的内皮细胞植入损伤血管的外膜表面,可以调节血管修复。在本研究中,我们开发了一种组织工程化内皮细胞的颗粒制剂,并开发了一种使用经皮微创技术向损伤血管周围血管内递送制剂的方法。
将不锈钢支架植入 9 头国内猪的 18 个球囊损伤股动脉中,随后在超声引导下经皮向支架周围注射含有培养的同种异体猪主动脉内皮细胞(PAE)的明胶颗粒。对照组在支架植入后接受空颗粒(基质)或无周围血管内注射(假手术)。动物在 90 天后处死。
血管造影分析显示,接受 PAE/基质治疗的支架段血管的管腔直径明显大于基质(4.01 ± 0.20mm)或假手术(4.03 ± 0.16mm)对照组(P <.05)。同样,组织学分析显示,与对照组(分别为 16.1 ± 0.9mm²和 17.1 ± 1.0mm²)相比,PAE/基质治疗的动脉具有最大的管腔面积(20.4 ± 0.7mm²;P <.05),而内膜面积最小(3.3 ± 0.4mm²;P <.05)与对照组(分别为 6.2 ± 0.5mm²和 4.4 ± 0.5mm²)。总的来说,与对照组相比,PAE 治疗的动脉闭塞率降低了 33%至 50%(P <.05)。组织病理学分析显示,PAE/基质组的内膜中白细胞较少,这表明生物效应部分是由于抑制了血管对损伤的炎症反应阶段。
使用超声引导经皮注射,将 PAE/基质微创、周围血管内递送至支架血管是安全的,显著降低了狭窄程度。在外周介入治疗时或之后应用,可能会降低临床再狭窄率。